Home | Welcome to Contract Pharma   
Last Updated Friday, May 24 2013
Print RSS Feed

Breaking News

Related Searches: Collaborations & Alliances •
Cobra, ViroMed Extend Agreement, May Form JV

July 28, 2008
Cobra Biomanufacturing has extended its recent manufacturing agreement with South Korea-based ViroMed Co. and the two companies plan to form a joint venture. The extended collaboration includes a long term-research, development and technical consulta…  Read More »
Millennium Starts Phase I Trials

July 28, 2008
Millennium, a division of Takeda, has begun two Phase I trials of MLN4924, a first-in-class, small molecule inhibitor of the Nedd 8 Activating Enzyme (NAE), a target discovered by the company. MLN4924 advanced to the clinic with the first patient dos…  Read More »
Azopharma Adds Formulations Equipment

July 25, 2008
Azopharma Product Development Group, Inc. has added new equipment at its formulation and manufacturing division, ApiCross Drug Delivery Technologies in Hollywood, FL. The company added the MG Futura Capsule Filler and Bausch & Strobel Aseptic Fil…  Read More »
Symyx Signs Research Services Pact with BMS

July 25, 2008
Symyx Technologies, Inc. launched its new client-directed and collaborative research services for Life Sciences. These services allow clients to access Symyx’s installed base of parallel experimentation and testing capabilities through packaged…  Read More »
FDA Grants Pediatric Exclusivity for Topamax

July 25, 2008
Ortho-McNeil Neurologics, a division of Ortho-McNeil-Janssen Pharmaceuticals, Inc., itself a division of Johnson & Johnson, received approval from the FDA for pediatric exclusivity for Topamax for use in patients aged 1 to 24 months with partial…  Read More »
Financial Report: Lilly 2Q

July 24, 2008
Lilly 2Q Revenues: $5.2 billion (+11%) 2Q Earnings: $958.8 million (+44%) YTD Revenues: $10.0 billion (+12%) YTD Earnings: $2.0 billion (+73%) Comments: Alimta, Byetta, Cialis, Cymbalta, Forteo, Strattera, Symbyax, Xigris and Yentreve,…  Read More »
Financial Report: Bristol-Myers Squibb 2Q

July 24, 2008
Bristol-Myers Squibb   2Q Revenues: $5.2 billion (+16%) 2Q Earnings: $764.0 million (+8%) YTD Revenues: $10.1 billion (+19%) YTD Earnings: $1.4 billion  (+2%) Comments: Pharmaceutical sales in the quarter were $4.5 billion (+…  Read More »
PPD, Inc.

July 24, 2008
Christine Dingivan, M.D. has been appointed executive vice president and chief medical officer, PPD, Inc. Dr. Dingivan provides strategic direction for global regulatory affairs and pharmacovigilance, biomarker discovery sciences, Phase I, and bioana…  Read More »
Financial Report: Pfizer 2Q

July 23, 2008
Pfizer 2Q Revenues: $12.1 billion (+9%) 2Q Earnings: $2.8 billion (+119%) YTD Revenues: $24.0 billion (+2%) YTD Earnings: $5.6 billion (+19%) Comments: Pharmaceutical sales in the quarter were $11.1 billion (+9%) and $22.0 billion YTD…  Read More »
Financial Report: Wyeth 2Q

July 23, 2008
Wyeth  2Q Revenues: $5.9 billion (+5%)   2Q Earnings: $1.1 billion (-6%) YTD Revenues: $11.7 billion (+6%) YTD Earnings: $2.3 billion (-5%) Comments: Pharmaceutical sales were $5.0 billion (+5%), due to Effexor, Enbrel, Prev…  Read More »
Financial Report: Genzyme 2Q

July 23, 2008
Genzyme 2Q Revenues: $1.2 billion (+25%) 2Q Earnings: $69.6 million (-17%) YTD Revenues: $2.3 billion (+25%) YTD Earnings: $214.8 million (-11%) Comments: Myozyme sales were up 65% in the quarter to $77.2 million. The company is still…  Read More »
BMS, AZ Submit NDA and MAA for Onglyz

July 23, 2008
Bristol-Myers Squibb and AstraZeneca have submitted an NDA to the FDA and a MAA to the EMEA for Onglyza (saxagliptin) for the treatment of type 2 diabetes.       The submissions are based on data from a clinical program conduct…  Read More »
Financial Report: Schering-Plough 2Q

July 22, 2008
Schering-Plough 2Q Revenues: $4.9 billion (+55%) 2Q Earnings: $436 million (-16%) YTD Revenues: $9.6 billion (+56%) YTD Earnings: $726 million (-34%) Comments: Pharmaceutical sales were $3.7 billion in the quarter (+47%) and $7.3 billi…  Read More »
Financial Report: Merck 2Q

July 22, 2008
Merck 2Q Revenues: $6.1 billion (-1%) 2Q Earnings: $1.8 billion (+5%) YTD Revenues: $11.9 billion (flat) YTD Earnings: $5.1 billion (+50%) Comments: Worldwide sales of Singulair were $1.1 billion in the quarter (-1%). Combined worldwid…  Read More »
Financial Report: Biogen Idec 2Q

July 22, 2008
Biogen Idec 2Q Revenues: $993 million (+28%) 2Q Earnings: $207 million (+11%) YTD Revenues: $1.9 billion (+30%) YTD Earnings: $369.7 million (+16%) Comments: Growth in the quarter was driven by Avonex sales up 14% to $527 million, Tysa…  Read More »

Receive free Contract Pharma Direct emails
Sign up now to receive the weekly newsletter, and more!

Enter your email address:

Follow Contract Pharma On
Please visit our sister sites: